Kodiak Sciences Inc (KOD)

Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus - Yahoo Finance

Yahoo Finance

Kodiak Sciences dosing subjects in Phase III trial of diabetic retinopathy drug - Clinical Trials Arena

Clinical Trials Arena

Why Is Kodiak Sciences Inc. (KOD) Down 26.3% Since Last Earnings Report? - Yahoo Canada Shine On

Yahoo Canada Shine On

Age-related Macular Degeneration Market to Exhibit Substantial Growth Rate - openPR

openPR

Age-related Macular Degeneration Market to Exhibit Substantial Growth Rate | Regeneron Pharmaceuticals, Novartis ... - Barchart

Barchart

Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including ... - Investing.com India

Investing.com India

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully - Simply Wall St

Simply Wall St

The Kodiak Sciences Inc (KOD) had a good session last reading, didn't it? – US Post News - US Post News

US Post News

Will Kodiak Sciences (NASDAQ:KOD) Spend Its Cash Wisely? - Yahoo Finance

Yahoo Finance

Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks

Zacks Investment Research

Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus

Zacks Investment Research

Take the Zacks Approach to Beat the Market: NVIDIA, Dell, Modine in Focus

Zacks Investment Research

Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus - Zacks Investment Research

Zacks Investment Research

Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

US Stocks Flat; Initial Jobless Claims Fall To 210,000

Benzinga

Kodiak Sciences Inc (KOD) Posts Q4 and Full Year 2023 Financial Results - GuruFocus.com

GuruFocus.com

Merck (MRK) Unit to Buy Elanco's Aqua Business for $1.3B

Zacks Investment Research

Vertex's (VRTX) Q4 Earnings and Sales Surpass Estimates

Zacks Investment Research

Kodiak Sciences patent describes NLRP3 inflammasome inhibitors - BioWorld Online

BioWorld Online

TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up

Zacks Investment Research

Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug Aduhelm

Zacks Investment Research

Dr. Reddy's (RDY) Q3 Earnings and Revenues Surpass Estimates

Zacks Investment Research

Kodiak Sciences Inc. (KOD) Up 43.6% Since Last Earnings Report: Can It Continue?

Zacks Investment Research

Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

EyePoint (EYPT) Surges 178% on Upbeat Phase II Eye Disease Data

Zacks Investment Research

Oxurion to file for bankruptcy following trial failure - Clinical Trials Arena

Clinical Trials Arena

Why Dolby Laboratories Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga

Kodiak Sciences Inc (KOD) Reports Q3 2023 Financial Results: Net Loss Narrows, R&D Expenses ... - Yahoo Finance

Yahoo Finance

KOD Stock Quote Price and Forecast - CNN

CNN

Diabetic Retinopathy Market to Register Incremental Growth by 2032, Asserts DelveInsight | Leading Companies in the ... - GlobeNewswire

GlobeNewswire

Kodiak's shelved tarcocimab succeeds in RVO trial - Clinical Trials Arena

Clinical Trials Arena

Age-Related Macular Degeneration Market to Grow Rapidly by 2032, Predicts DelveInsight | Key Companies - Opthea ... - GlobeNewswire

GlobeNewswire

Kodiak CMO Steps Down After Phase III Flops for Eye Therapy - BioSpace

BioSpace

Kodiak Sciences Inc. (NASDAQ:KOD) Is Expected To Breakeven In The Near Future - Yahoo Finance

Yahoo Finance

Why Is Kodiak Sciences (KOD) Stock Down 58% Today? - InvestorPlace

InvestorPlace

Kodiak Sciences begins subject treatment in DME therapy trial - Clinical Trials Arena

Clinical Trials Arena

Nanoscope Therapeutics announces WHO selection of 'sonpiretigene isteparvovec' as international nonproprietary ... - Modern Retina

Modern Retina

Kodiak: Turnaround Strategy Has Shown Life Thus Far (NASDAQ:KOD) - Seeking Alpha

Seeking Alpha

Wet AMD Clinical Trials Pipeline Analysis Featuring 70+ Key Companies by DelveInsight - GlobeNewswire

GlobeNewswire

Kodiak Sciences Stock: The Busted Biotech World (NASDAQ:KOD) - Seeking Alpha

Seeking Alpha

Kodiak Sciences Stock: Expecting Sentiment To Turn Bullish - Seeking Alpha

Seeking Alpha

Why Kodiak Sciences Stock Is Sharply Lower Today - The Motley Fool

The Motley Fool

Lonza and Kodiak open custom-built bioconjugation facility - European Pharmaceutical Review

European Pharmaceutical Review

Kodiak Sciences rises after director Baker Bros Advisors buys shares worth ~$4.4M - Seeking Alpha

Seeking Alpha

Grand Opening Of Kodiak Sciences’ Bioconjugation Facility - Contract Pharma

Contract Pharma

Kodiak Sciences Stock: Potential For Comeback After Trial Setback (NASDAQ:KOD) - Seeking Alpha

Seeking Alpha

KSI-301 Disappoints (NASDAQ:KOD) - Seeking Alpha

Seeking Alpha

Peninsula biotech stock loses 80% after eye drug's late-stage study fails - San Francisco Business Times - The Business Journals

The Business Journals

Surgeon completes first successful implantation of wireless visual prosthesis brain implant - Ophthalmology Times

Ophthalmology Times

Palo Alto's Kodiak Sciences just turned down a $125M investment. Here's why. - Silicon Valley Business Journal - The Business Journals

The Business Journals